{"hands_on_practices": [{"introduction": "This practice challenges you to think like a bioengineer or, indeed, like evolution itself. By designing a regulatory circuit for a branched metabolic pathway, you will explore the fundamental logic of how cells achieve independent control over different products that share a common precursor. This exercise reveals the core principles of metabolic efficiency and precision that are essential for cellular life [@problem_id:2295343].", "problem": "A bioengineering firm is modifying a bacterial strain to produce two distinct, commercially valuable secondary metabolites, Compound $X$ and Compound $Y$. The synthesis of these compounds originates from a common cellular precursor, Metabolite $A$. The simplified metabolic pathway is as follows:\n\n1.  Metabolite $A$ is converted to Intermediate $B$ by Enzyme $E_1$.\n2.  Intermediate $B$ is the branch point.\n3.  The pathway to Compound $X$ proceeds from Intermediate $B$, which is converted to Intermediate $C$ by Enzyme $E_2$, and then Intermediate $C$ is converted to the final product Compound $X$ by Enzyme $E_3$.\n4.  The pathway to Compound $Y$ proceeds from Intermediate $B$, which is converted to Intermediate $D$ by Enzyme $E_4$, and then Intermediate $D$ is converted to the final product Compound $Y$ by Enzyme $E_5$.\n\nThe firm needs to implement a negative feedback regulation system to ensure that the production of each compound can be independently controlled. For instance, if the cell has accumulated a sufficient amount of Compound $X$, its synthesis should be selectively shut down without affecting the synthesis of Compound $Y$, and vice versa. Several potential regulatory schemes have been proposed. Which of the following feedback inhibition schemes would be the most effective and metabolically efficient for achieving this independent regulation?\n\nA. Compound $X$ allosterically inhibits Enzyme $E_2$, and Compound $Y$ allosterically inhibits Enzyme $E_4$.\n\nB. Both Compound $X$ and Compound $Y$ allosterically inhibit Enzyme $E_1$.\n\nC. Compound $X$ allosterically inhibits Enzyme $E_4$, and Compound $Y$ allosterically inhibits Enzyme $E_2$.\n\nD. Compound $X$ allosterically inhibits Enzyme $E_3$, and Compound $Y$ allosterically inhibits Enzyme $E_5$.\n\nE. Metabolite $A$ allosterically inhibits both Enzyme $E_3$ and Enzyme $E_5$.", "solution": "Goal: implement negative feedback allowing independent control of the two branches that diverge at the common branch point. The correct design principle is end-product inhibition of the first committed, branch-specific step so that (i) accumulation of a given product selectively shuts its own branch without affecting the other branch, and (ii) flux is halted as early as possible to avoid wasteful accumulation of intermediates and unnecessary consumption of precursors and energy.\n\nIdentify the branch-specific first committed steps:\n- For production of $X$, the first reaction unique to this branch is $B \\xrightarrow{E_{2}} C$. Therefore, $X$ should inhibit $E_{2}$.\n- For production of $Y$, the first reaction unique to this branch is $B \\xrightarrow{E_{4}} D$. Therefore, $Y$ should inhibit $E_{4}$.\n\nEvaluate each option against these criteria:\n- Option A: $X$ allosterically inhibits $E_{2}$ and $Y$ allosterically inhibits $E_{4}$. This implements end-product inhibition at the first committed step in each branch. It provides independent control: accumulation of $X$ reduces only the $B \\to C$ flux, leaving $B \\to D$ unaffected; accumulation of $Y$ reduces only the $B \\to D$ flux, leaving $B \\to C$ unaffected. It is also metabolically efficient because it halts flux at the earliest branch-unique step, minimizing buildup of intermediates and unnecessary use of $A$.\n- Option B: Both $X$ and $Y$ inhibit $E_{1}$. Because $E_{1}$ is upstream of the branch point and common to both products, accumulation of either $X$ or $Y$ would suppress flux to both branches, violating the requirement for independent regulation and reducing metabolic efficiency when only one product is in excess.\n- Option C: $X$ inhibits $E_{4}$ and $Y$ inhibits $E_{2}$. This cross-inhibition creates negative coupling between branches: accumulation of $X$ throttles the $Y$ branch and vice versa. It does not provide independent regulation and is counter to the design goal.\n- Option D: $X$ inhibits $E_{3}$ and $Y$ inhibits $E_{5}$. Inhibiting the terminal enzymes allows continued flux through $E_{2}$ and $E_{4}$, causing accumulation of intermediates $C$ and $D$ and wasted consumption of $A$ and cofactors. This is less metabolically efficient and does not stop the branch at its first committed step.\n- Option E: $A$ inhibits $E_{3}$ and $E_{5}$. This is not end-product feedback and is not responsive to levels of $X$ or $Y$. It fails to achieve selective shutdown when $X$ or $Y$ accumulates, and it also targets terminal steps with the same inefficiency noted above.\n\nTherefore, the most effective and metabolically efficient scheme for independent regulation is end-product inhibition at the first committed step of each branch, as in Option A.", "answer": "$$\\boxed{A}$$", "id": "2295343"}, {"introduction": "Moving from design to quantitative analysis, this problem demonstrates the tangible consequences of a broken feedback loop. By comparing a normal metabolic pathway to a mutant version with a non-functional regulatory site, you will apply kinetic equations to calculate the specific impact on metabolite concentrations [@problem_id:2046266]. This exercise highlights just how critical feedback inhibition is for maintaining metabolic homeostasis and preventing the wasteful accumulation of intermediates.", "problem": "Consider a simplified linear metabolic pathway in a bacterial cell, which converts a substrate A into a final product D through two intermediate compounds, B and C:\n\n$A \\xrightarrow{E_1} B \\xrightarrow{E_2} C \\xrightarrow{E_3} D$\n\nThe first enzyme in the pathway, $E_1$, is an allosteric enzyme that is subject to non-competitive feedback inhibition by the final product, $D$. The other enzymes, $E_2$ and $E_3$, are not subject to regulation. All enzymes in the pathway follow Michaelis-Menten kinetics.\n\nThe system operates under the following conditions:\n1.  The concentration of the initial substrate, $[A]$, is maintained at a constant, saturating level, such that it is much greater than the Michaelis constant of $E_1$ ($K_{M,1}$).\n2.  The pathway has reached a steady state, meaning the rates of production and consumption for each intermediate (B and C) are equal, and their concentrations are constant.\n3.  In a normal, wild-type cell, homeostatic mechanisms maintain the concentration of the final product $D$ at a constant level equal to three times its inhibition constant for $E_1$ (i.e., $[D]_{\\text{wt}} = 3 K_I$, where $K_I$ is the inhibition constant).\n\nNow, consider a mutant strain of the bacterium. This strain possesses a mutation in the gene encoding for enzyme $E_1$. The resulting mutant enzyme, $E_{1,\\text{mut}}$, has the same catalytic properties ($V_{\\text{max},1}$ and $K_{M,1}$) as the wild-type enzyme, but its regulatory (allosteric) site is non-functional, completely preventing the binding of the inhibitor $D$.\n\nGiven the following kinetic parameters for the wild-type enzymes:\n-   Maximum velocity of $E_1$, $V_{\\text{max},1} = 0.50$ mM/s\n-   Maximum velocity of $E_2$, $V_{\\text{max},2} = 1.00$ mM/s\n-   Michaelis constant of $E_2$, $K_{M,2} = 1.50$ mM\n\nCalculate the ratio of the steady-state concentration of intermediate B in the mutant strain, $[B]_{\\text{mut}}$, to that in the wild-type strain, $[B]_{\\text{wt}}$. Express your answer as a single real number.", "solution": "Because all enzymes follow Michaelis-Menten kinetics and the pathway is at steady state, the production and consumption rates of intermediate B are equal:\n$$v_{1} = v_{2}$$\nFor non-competitive inhibition of $E_{1}$ by $D$, the apparent maximum velocity is reduced while $K_{M,1}$ is unchanged. With $[A] \\gg K_{M,1}$, the rate of $E_{1}$ equals its apparent $V_{\\text{max}}$:\n$$v_{1,\\text{wt}} = \\frac{V_{\\text{max},1}}{1 + \\frac{[D]_{\\text{wt}}}{K_{I}}}$$\nGiven $[D]_{\\text{wt}} = 3 K_{I}$, we obtain:\n$$v_{1,\\text{wt}} = \\frac{V_{\\text{max},1}}{1 + 3} = \\frac{V_{\\text{max},1}}{4}$$\nIn the mutant, the inhibitor cannot bind, so with $[A]$ saturating:\n$$v_{1,\\text{mut}} = V_{\\text{max},1}$$\nThe $E_{2}$ step follows Michaelis-Menten kinetics with substrate $B$:\n$$v_{2} = \\frac{V_{\\text{max},2}\\,[B]}{K_{M,2} + [B]}$$\nAt steady state for each strain, since $v_{1} = v_{2}$, let's call the rate $v$. Then $v = \\frac{V_{\\text{max},2}\\,[B]}{K_{M,2} + [B]}$.\nRearranging for $[B]$ gives:\n$$v \\left(K_{M,2} + [B]\\right) = V_{\\text{max},2}\\,[B]$$\n$$v\\,K_{M,2} = \\left(V_{\\text{max},2} - v\\right)[B]$$\n$$[B] = \\frac{v\\,K_{M,2}}{V_{\\text{max},2} - v}$$\nApplying this to wild-type (where $v = v_{1,\\text{wt}}$) and mutant (where $v=v_{1,\\text{mut}}$) strains:\n$$[B]_{\\text{wt}} = \\frac{\\left(\\frac{V_{\\text{max},1}}{4}\\right) K_{M,2}}{V_{\\text{max},2} - \\frac{V_{\\text{max},1}}{4}}, \\quad [B]_{\\text{mut}} = \\frac{V_{\\text{max},1}\\,K_{M,2}}{V_{\\text{max},2} - V_{\\text{max},1}}$$\nTheir ratio simplifies to:\n$$\\frac{[B]_{\\text{mut}}}{[B]_{\\text{wt}}} = \\frac{\\frac{V_{\\text{max},1}\\,K_{M,2}}{V_{\\text{max},2} - V_{\\text{max},1}}}{\\frac{\\left(\\frac{V_{\\text{max},1}}{4}\\right) K_{M,2}}{V_{\\text{max},2} - \\frac{V_{\\text{max},1}}{4}}} = \\frac{V_{\\text{max},1}}{V_{\\text{max},2} - V_{\\text{max},1}} \\cdot \\frac{V_{\\text{max},2} - \\frac{V_{\\text{max},1}}{4}}{\\frac{V_{\\text{max},1}}{4}} = 4\\,\\frac{V_{\\text{max},2} - \\frac{V_{\\text{max},1}}{4}}{V_{\\text{max},2} - V_{\\text{max},1}}$$\nSubstituting the given values $V_{\\text{max},1} = 0.50$ mM/s and $V_{\\text{max},2} = 1.00$ mM/s (units cancel in the ratio):\n$$\\frac{[B]_{\\text{mut}}}{[B]_{\\text{wt}}} = 4 \\cdot \\frac{1.00 - \\frac{0.50}{4}}{1.00 - 0.50} = 4 \\cdot \\frac{1.00 - 0.125}{0.50} = 4 \\cdot \\frac{0.875}{0.50} = 4 \\cdot 1.75 = 7$$\nTherefore, the mutant has a sevenfold higher steady-state concentration of intermediate B compared to the wild type.", "answer": "$$\\boxed{7}$$", "id": "2046266"}, {"introduction": "Real metabolic pathways do not exist in isolation but are part of a complex, interconnected network. This final practice situates feedback inhibition within a larger, compartmentalized cellular system, linking glycolysis, the citric acid cycle, and fatty acid synthesis [@problem_id:2046265]. Your task is to deduce the cascading, system-wide effects stemming from a single molecular disruption, thereby developing a more holistic and realistic understanding of metabolic regulation.", "problem": "In a particular strain of eukaryotic cells, the metabolic pathway for fatty acid synthesis relies on a supply of acetyl-CoA in the cytosol. This cytosolic acetyl-CoA is generated from citrate that is first synthesized in the mitochondrial matrix via the citric acid cycle and then exported to the cytosol via the mitochondrial tricarboxylate transporter. These cells are cultured in a glucose-rich medium.\n\nThe activities of three key enzymes are central to this metabolic network:\n1.  **Phosphofructokinase-1 (PFK-1):** A cytosolic enzyme that is a major regulatory point in glycolysis. It is allosterically inhibited by high concentrations of cytosolic citrate.\n2.  **Pyruvate Dehydrogenase Complex (PDH):** A mitochondrial enzyme complex that converts pyruvate (from glycolysis) into acetyl-CoA. It is inhibited by its products, acetyl-CoA and NADH.\n3.  **Citrate Synthase (CS):** A mitochondrial enzyme that catalyzes the first step of the citric acid cycle, combining acetyl-CoA and oxaloacetate to form citrate. It is subject to product inhibition by citrate.\n\nConsider a mutant strain of these cells that possesses a complete loss-of-function mutation in the gene encoding the mitochondrial tricarboxylate transporter. After the cells reach a new metabolic steady-state, how will the activities of PFK-1, PDH, and CS in the mutant strain compare to those in the wild-type (non-mutant) cells?\n\nSelect the option that correctly describes the change in steady-state activity for each enzyme.\n\nA. PFK-1: Increase, PDH: Decrease, CS: Decrease\n\nB. PFK-1: Decrease, PDH: Increase, CS: Increase\n\nC. PFK-1: Decrease, PDH: Decrease, CS: Decrease\n\nD. PFK-1: Increase, PDH: Increase, CS: Decrease\n\nE. PFK-1: No Significant Change, PDH: Decrease, CS: Decrease", "solution": "In the wild-type cells, citrate produced in the mitochondrial matrix by citrate synthase (CS) is exported to the cytosol via the mitochondrial tricarboxylate transporter. In the cytosol, citrate both serves as a source of acetyl-CoA (via ATP citrate lyase) for fatty acid synthesis and allosterically inhibits phosphofructokinase-1 (PFK-1). In the mitochondrion, citrate exerts product inhibition on CS. The pyruvate dehydrogenase complex (PDH) is inhibited by its products acetyl-CoA and NADH.\n\nIn the mutant with a complete loss of the mitochondrial tricarboxylate transporter, the export of citrate from mitochondria to cytosol is abolished. At the new steady state, this has the following consequences:\n\n1) Cytosolic citrate decreases. Because citrate cannot be exported, the cytosolic concentration $[\\text{citrate}]_{\\text{cytosol}}$ falls relative to wild-type. Since PFK-1 is allosterically inhibited by cytosolic citrate, its rate $v_{\\text{PFK-1}}$ is a decreasing function of $[\\text{citrate}]_{\\text{cytosol}}$, i.e., $\\frac{\\partial v_{\\text{PFK-1}}}{\\partial [\\text{citrate}]_{\\text{cytosol}}}<0$. Therefore, a decrease in $[\\text{citrate}]_{\\text{cytosol}}$ relieves inhibition, leading to an increase in PFK-1 activity at steady state.\n\n2) Mitochondrial citrate increases and inhibits CS. With export blocked, citrate formed by CS is no longer removed to the cytosol, so $[\\text{citrate}]_{\\text{mitochondria}}$ increases relative to wild-type unless fully balanced by increased downstream flux. In glucose-rich, lipogenic conditions, high energy charge and elevated $[\\text{NADH}]_{\\text{mitochondria}}$ limit tricarboxylic acid flux, favoring citrate accumulation. Because CS is subject to product inhibition by citrate, its rate $v_{\\text{CS}}$ decreases as $[\\text{citrate}]_{\\text{mitochondria}}$ increases, so CS activity decreases.\n\n3) PDH is inhibited by accumulating acetyl-CoA and NADH. Blocking citrate export removes an important sink for acetyl-CoA (via CS to citrate destined for export). As CS activity falls due to product inhibition, the consumption of acetyl-CoA to form citrate is further curtailed. Consequently, $[\\text{acetyl-CoA}]_{\\text{mitochondria}}$ increases, directly inhibiting PDH. In addition, reduced tricarboxylic acid throughput elevates $[\\text{NADH}]_{\\text{mitochondria}}$, which also inhibits PDH. Hence the PDH rate $v_{\\text{PDH}}$ decreases at steady state despite increased pyruvate supply from enhanced glycolysis.\n\nPutting these regulatory effects together:\n- PFK-1 activity increases (less cytosolic citrate inhibition),\n- PDH activity decreases (more mitochondrial acetyl-CoA and NADH product inhibition),\n- CS activity decreases (more mitochondrial citrate product inhibition).\n\nThis pattern corresponds to option A.", "answer": "$$\\boxed{A}$$", "id": "2046265"}]}